NEW YORK – ERS Genomics said on Wednesday that it has granted research reagent provider GenScript Biotech a nonexclusive license to its CRISPR-Cas9 patent portfolio, which GenScript said it will use to strengthen its own CRISPR-based services.
Financial and other terms of the deal were not disclosed.
Dublin-based ERS Genomics was founded to provide access to CRISPR-Cas9 intellectual property held by Emmanuelle Charpentier. The IP is shared between her, Jennifer Doudna and the University of California, and the University of Vienna and is separate from genome editing patents held by the Broad Institute.
GenScript is a global biotech firm that provides life sciences research and application products and services, with offices in the US, the Asia-Pacific region, and Europe. The company said its oligonucleotide and gene synthesis technology is applicable to various fields, from basic life science research to translational biomedical development, industrial synthetic products, and cell therapeutic solutions. GenScript will use the license from ERS to improve its synthetic sgRNA, gRNA plasmid, gRNA library, and cell line engineering services.
ERS frequently licenses its CRISPR-Cas9 portfolio to other companies. Its most recent agreement was with Waltrop, Germany-based Nuvisan, which said it will use ERS' technology to help advance its clients' drug discovery and early development programs.